

**Amendments to the Claims:**

This listing of the claims replaces all prior versions of the claims.

**CLAIMS:**

1. (Withdrawn) A vaccine for mucosal administration comprising: A) a double-stranded RNA; and B) a subunit antigen or inactivated antigen of a pathogen.
2. (Withdrawn) The vaccine of claim 1, wherein said mucosa comprises the nasal mucosa.
3. (Withdrawn) The vaccine of claim 1, wherein said pathogen is selected from the group consisting of varicella virus, measles virus, mumps virus, poliovirus, rotavirus, influenza virus, adenovirus, herpes virus, rubella virus, severe acute respiratory syndrome virus (SARS virus), human immunodeficiency virus (HIV), Bordetella pertussis, Neisseria meningitidis, Haemophilus influenzae type b, Streptococcus pneumoniae and Vibrio cholerae.
4. (Withdrawn) The vaccine of claim 1, wherein said pathogen is an influenza virus.
5. (Withdrawn) The vaccine of claim 1, wherein said subunit comprises at least one subunit selected from the group consisting of the influenza virus subunits HA, NA, M1, M2, NP, PB1, PB2, PA and NS2.
6. (Withdrawn) The vaccine of claim 1, wherein said double-stranded RNA is present at a concentration sufficient to produce secretory IgA.
7. (Withdrawn) The vaccine of claim 1, wherein said double-stranded RNA is present at a concentration of 0.1 to 10 mg/ml.
8. (Withdrawn) The vaccine of claim 1, wherein the size of said double-stranded RNA is  $10^2$ - $10^8$  bp.
9. (Withdrawn) The vaccine of claim 1, wherein said subunit comprises at least NA or HA.
10. (Withdrawn) The vaccine of claim 1, wherein said double stranded RNA comprises Poly(I:C).
11. (Currently amended) A method of preventing influenza ~~an infectious disease~~, comprising a step of ~~for~~ ~~mucosally~~ administering to nasal mucosa at least once:

A) a vaccine at a concentration sufficient to produce secretory IgA for mucosal administration comprising: a) a double-stranded RNA; and  
b) a subunit antigen or inactivated antigen of an influenza virus; and a  
pathogen  
c) water or a physiological solution or an artificial cerebrospinal fluid.

12. (Original) The method of claim 11, wherein said vaccine is administered at least twice.
13. (Original) The method of claim 11, wherein said vaccine is administered at an interval of at least 1 week or more.
14. (Original) The method of claim 11, wherein said double-stranded RNA comprises Poly(I:C).
15. (Withdrawn) A vaccine kit for preventing an infectious disease, provided with:  
A) a vaccine for mucosal administration comprising: a) a double-stranded RNA; and  
b) a subunit antigen or inactivated antigen of a pathogen; and B) an instruction sheet directing to mucosally administer said vaccine at least once.
16. (Withdrawn) The kit of claim 15, wherein the aforementioned vaccine is administered at least twice.
17. (Withdrawn) The kit of claim 15, wherein said vaccine is administered at an interval of at least 1 week or more.
18. (Withdrawn) The kit of claim 15, wherein said double-stranded RNA comprises Poly(I:C).
- 19 -22. (canceled)